Insight

Kunal Jobanputra Shares Key Clinical Studies from ASCO 2025

Kunal Jobanputra/researchgate.net

May 25, 2025, 14:50

Kunal Jobanputra Shares Key Clinical Studies from ASCO 2025

Kunal Jobanputra, Community Medical Oncologist at Tata Memorial Hospital, shared some studies from ASCO 2025:

Immunological approach to cancer interception by DNA plasmid vaccine

” ‘Immunological approach to cancer interception by DNA plasmid vaccine’ Phase IB study. INO-5401 encoding hTERT, PSMA and WT1, +/- IL12 and electroporation in healthy individuals with BRCA1/2 without cancer – Safety data so far.”

CATNON results

“Final CATNON results for anaplastic glioma without co-deletion:

Adjuvant TMZ boosts OS in IDH-mutant (HR 0.54, p<0.0001; median 12.5 yrs). No benefit in IDH-wt.
RT + 12 cycles adjuvant TMZ – standard for IDH-mt
Concurrent TMZ did not improve OS regardless of IDH status.”

UCPVax in IDH1-wt GBM

“UCPVax in IDH1-wt GBM: to stimulate CD4+ helper T cell responses against telomerase (TERT)

Design: Phase IIa, 2-cohort; post-chemoradiation; Cohort A: vaccine alone; Cohort B: vaccine + 6 mo TMZ. Population: 61 patients (31 Cohort A: unmethylated MGMT; 30 Cohort B: 50% unmethylated). Outcomes: 83% (A) and 69% (B) had TERT-CD4+ response. 53% epitope spreading (57.7% A, 48% B)

OS 19.3 vs 12.8 mo with spread (P=0.03); RR 50% with spread vs 18.7% (P=0.05); safe, no serious AEs. Further trials for TERT vaccine in GBM. Effect of TMZ-lymphopenia on epitope spreading?”

RANO classification for extent of resection

“RANO classification for extent of resection. Population: Grade 2 IDH-mutant (379 astrocytoma, 349 oligodendroglioma) – who did not receive adjuvant Rx were allowed to study effects of resection.

Class 1 (Supramaximal): Resection beyond T2/FLAIR borders (0 cm³ remnant), 10-yr OS 97.5%.
Class 2 (Maximal): 0-5 cm³ remnant, 10-yr OS 82.2%.
Class 3 (Submaximal): 5-25 cm³ remnant, 10-yr OS 75%.
Class 4 (Minimal): >25 cm³ remnant, 10-yr OS 45.6%.”

Off-label use of T-DXd in Desmoplastic Small Round cell Tumor

“Off-label use of T-DXd in Desmoplastic Small Round cell Tumor, study from Memorial Sloan Kettering Cancer Center.

Studied HER2 by IHC (CB11 and 4B5) and also expression by RNA-seq in DSRCT
CB11 IHC showed 38/52 cases with > 10% HER2 staining and RNA-seq had third highest HER2 expression among pediatric solid tumors
Used in 16 patients with R/R DSRCT: 50% PR (8/16), 100% clinical benefit
8/8 had prior exposure to irinotecan
No response correlation with IHC/RNAseq.”

CARv3-TEAM-E to tackle challenge of heterogeneity with conventional CAR-T in GBM

“CARv3-TEAM-E to tackle challenge of heterogeneity with conventional CAR-T in GBM: T cells targeting EGFRvIII + T-cell-Engaging Antibody Molecules (TEAMs) against wild-type EGFR in recurrent GBM. Intraventricularly delivered CARv3-TEAM-E T cells were detected in the CSF and peripheral blood. Subsequent infusions – Ab development.”

OASIS 4 phase 3 trial

“OASIS 4 ph3 trial

Elinzanetant: a dual NK1/NK3 antagonist
For vasomotor symptoms in HR+ breast cancer patients on adjuvant ET
Elinzanetant reduced vasomotor symp frequency at week 4 (-6.5 vs -3.0, p<0.0001) and week 12 (-7.8 vs -4.2, p<0.0001).”

NeoADAURA

“NeoADAURA: EGFRm (Ex19del/L858R) stg II–IIIB (AJCC 8th ed)

1:1:1 to

neoadj osi 80 mg QD (≥9 weeks) + CT

Osi monotherapy 80 mg QD (≥9 weeks) or

Placebo + CT

Osi/PBO + CT: double blind; osi mono: open label, sponsor blind. Adj osi was offered to all patients who completed surgery. Primary endpoint: MPR. Neoadjuvant Osi +/- CT showed improved MPR vs CT alone.”